tributoxymethylsilane | CAS:5581-68-0

We serve tributoxymethylsilane CAS:5581-68-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
tributoxymethylsilane

Chemical Name:tributoxymethylsilane
CAS.NO:5581-68-0
Synonyms:Methyltri-n-butoxysilane; tributoxy-methyl-silane; Tributyloxy-methyl-silan; Tributoxy-methyl-silan;
Molecular Formula:C13H30O3Si
Molecular Weight:262.46100
 
Physical and Chemical Properties:
Density:0.88;
Boiling point:213.6oC;
Flash point:93.7oC;
Index of Refraction:1.425;
 
Specification:
Appearance:Colorless clear liquid
Purity(GC):≥97.0%
 
Packing:210 L/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:It is used in the pharmaceutical and chemical industry.



Contact us for information like tributoxymethylsilane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Tributoxy-methyl-silan physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,tributoxy-methyl-silane Use and application,tributoxy-methyl-silane technical grade,usp/ep/jp grade.


Related News: Capacity: the bottleneck of business growth, expanding capacity and increasing utilization become a trend. Capacity is the core factor that determines the supply capacity of API companies. Insufficient capacity will cause companies to selectively complete orders and produce varieties, limiting the expansion of API products and market development.Diethylsilanediol manufacturer Capacity: the bottleneck of business growth, expanding capacity and increasing utilization become a trend. Capacity is the core factor that determines the supply capacity of API companies. Insufficient capacity will cause companies to selectively complete orders and produce varieties, limiting the expansion of API products and market development.2-Bromo-3-fluorobenzaldehyde supplier Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).9-Phenyl-9H-Carbazol-3-Ylboronic Acid vendor China is now dealing with another disease outbreak — this one mostly affecting animals but also potentially deadly among people.China is now dealing with another disease outbreak — this one mostly affecting animals but also potentially deadly among people.